MedTrace Logo

Incidence and Economic Burden of Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS)

NCT03141775 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 541

Last updated 2018-03-15

No results posted yet for this study

Summary

IBIS is a prospective, observational study, which aims to assess the cost of CDI per day, hospitalization and year including description of incremental costs in hospitalized patients, and recurrent episodes, in German hospitals. Exposure to CDI drugs will not be influenced and remains at the discretion of the treating physician.

In addition to treatment, Health-related quality of life (HRQL) will be analyzed using standardized questionnaires.

Conditions

  • Clostridium Difficile Infection
  • Clostridium Difficile Diarrhea

Interventions

OTHER

Treatment of CDI

Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Maria Vehreschild, MD · University Hospital of Cologne, Department of Internal Medicine / Infectious Diseases, Cologne, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2018-12-31
Completion
2019-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03141775 on ClinicalTrials.gov